Compare iShares Core MSCI EAFE ETF (IEFA) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core MSCI EAFE ETF vs ResMed Inc. — how do they compare? iShares Core MSCI EAFE ETF trades at $96.91, while ResMed Inc. trades at $196 (market cap $28.81B). The key difference: ResMed Inc. pays a 1.21% dividend while iShares Core MSCI EAFE ETF pays none, and iShares Core MSCI EAFE ETF is trading nearer its 52-week high, ResMed Inc. nearer its low. Which is the better fit depends on your goals.
| IEFA | RMD | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $98.56 | $293.73 |
52-Week Low | $81.70 | $182.82 |
Market Cap | — | $28.81B |
Enterprise Value | — | $27.99B |
Dividend Yield | — | 1.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEFA trades at $95.57, down 0.71% today amid a bearish technical signal. The ETF focuses on developed international equities excluding the U.S. and Canada, offering a 3.30% dividend yield with a low 0.07% expense ratio. Recent news highlights its role in diversification away from S&P 500 concentration risks. Key support and resistance levels are tightly clustered around $96-$97.
The outlook remains mixed; IEFA provides cost-effective exposure to stable international markets but faces headwinds from currency fluctuations and central bank policy shifts. Its bearish technical trend and neutral oscillators suggest near-term consolidation, while long-term investors may value its dividend income and geographic diversification benefits.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares Core MSCI EAFE ETF
IEFA tracks the MSCI EAFE Investable Market Index, offering broad exposure to large, mid, and small-cap stocks in developed markets across Europe, Australasia, and the Far East. It serves as a low-cost core holding for international diversification, excluding the U.S. and Canada.
Read more on IEFA →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
